ERBB2 and triple-negative breast carcinoma: Currently, the clinically common subtypes include luminal A type, luminal B type, human epidermal growth factor receptor-2 positive (HER2+), and triple-negative breast cancer (TNBC), and patients of different subtypes have different responses to treatment [2,3,4].